[go: up one dir, main page]

SV2010003595A - Tratamiento de cardiopatias usando b-bloqueantes - Google Patents

Tratamiento de cardiopatias usando b-bloqueantes

Info

Publication number
SV2010003595A
SV2010003595A SV2010003595A SV2010003595A SV2010003595A SV 2010003595 A SV2010003595 A SV 2010003595A SV 2010003595 A SV2010003595 A SV 2010003595A SV 2010003595 A SV2010003595 A SV 2010003595A SV 2010003595 A SV2010003595 A SV 2010003595A
Authority
SV
El Salvador
Prior art keywords
cardiopatias
blockers
treatment
procedure
cardiopathy
Prior art date
Application number
SV2010003595A
Other languages
English (en)
Inventor
Gerald Beddies
Axel Schmidt
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of SV2010003595A publication Critical patent/SV2010003595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN PROCEDIMIENTO PARA REVERTIR LA REMODELACIÓN CARDIACA ELECTROFISIOLÓGICA DE ANIMALES CON CARDIOPATÍA. MAS ESPECÍFICAMENTE, EL PROCEDIMIENTO INCLUYE ADMINISTRAR A UN ANIMAL QUE LO NECESITE UN BLOQUEANTE DE ADRENOCEPTORES BETA
SV2010003595A 2007-12-27 2010-06-11 Tratamiento de cardiopatias usando b-bloqueantes SV2010003595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1689107P 2007-12-27 2007-12-27

Publications (1)

Publication Number Publication Date
SV2010003595A true SV2010003595A (es) 2011-01-14

Family

ID=40456577

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003595A SV2010003595A (es) 2007-12-27 2010-06-11 Tratamiento de cardiopatias usando b-bloqueantes

Country Status (19)

Country Link
US (1) US20100305213A1 (es)
EP (1) EP2234609A1 (es)
JP (1) JP2011507918A (es)
KR (1) KR20100102640A (es)
CN (1) CN101909612A (es)
AU (1) AU2008342250A1 (es)
BR (1) BRPI0821483A2 (es)
CA (1) CA2710665A1 (es)
CO (1) CO6300936A2 (es)
CR (1) CR11501A (es)
EC (1) ECSP10010249A (es)
IL (1) IL205870A0 (es)
MX (1) MX2010006443A (es)
NI (1) NI201000096A (es)
RU (1) RU2010131022A (es)
SV (1) SV2010003595A (es)
TW (1) TW200942227A (es)
WO (1) WO2009083177A1 (es)
ZA (1) ZA201003867B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113148A1 (zh) * 2012-01-30 2013-08-08 Lin Shuguang β3肾上腺素受体阻滞剂的抗肿瘤用途
WO2016138908A1 (en) 2015-03-03 2016-09-09 Saniona A/S Tesofensine, beta blocker combination formulation
US11235029B2 (en) 2017-03-09 2022-02-01 Temple University-Of The Commonwealth System of Higher Methods for treating heart failure with a TRKB agonist
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN110269938A (zh) * 2019-06-27 2019-09-24 山东省眼科研究所 一种减轻铜绿假单胞菌性角膜炎症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung

Also Published As

Publication number Publication date
RU2010131022A (ru) 2012-02-10
ECSP10010249A (es) 2010-07-30
CR11501A (es) 2010-11-12
MX2010006443A (es) 2010-09-03
WO2009083177A1 (en) 2009-07-09
ZA201003867B (en) 2011-08-31
IL205870A0 (en) 2010-11-30
CA2710665A1 (en) 2009-07-09
JP2011507918A (ja) 2011-03-10
TW200942227A (en) 2009-10-16
CO6300936A2 (es) 2011-07-21
CN101909612A (zh) 2010-12-08
BRPI0821483A2 (pt) 2015-06-16
KR20100102640A (ko) 2010-09-24
AU2008342250A1 (en) 2009-07-09
US20100305213A1 (en) 2010-12-02
EP2234609A1 (en) 2010-10-06
NI201000096A (es) 2011-03-23

Similar Documents

Publication Publication Date Title
UY37324A (es) Compuestos bicíclicos como plaguicidas
MX2017007701A (es) Compuestos de modulacion de fxr (nr1h4).
BR112017013733A2 (pt) 5-fluoro-4-imino-3-(alquil/alquil substituído)-l- (arilsulfonil)-3,4-diidropirimidin-2(lh)-ona como um tratamento de semente
UY33317A (es) Nuevos derivados de pirazol
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
BR112012030408A2 (pt) método de melhoramento de culturas
BR112015027432B8 (pt) 3-(4-isobutil-2-metilfenil)propanal como ingrediente de perfume
NI201500140A (es) Compuestos y composiciones terapéuticos
CL2013000479A1 (es) Formulacion antimicrobiana que comprende un acido organico c1 a c24 y un aldehido alifatico insaturado; y metodo para el tratamiento del alimento de animales que la contiene
UY32296A (es) Nuevos compuestos
BR112012014990A2 (pt) composto, método para tratar uma doença ou condição dependente de calicreína de plasma, e, composição.
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
MX340928B (es) Derivados de oxazolina e isoxazolina como moduladores de canales de calcio de liberación activa (crac).
CO2018004473A2 (es) Compuestos agonistas de ppar y composiciones farmaceuticas
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
SV2010003595A (es) Tratamiento de cardiopatias usando b-bloqueantes
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
BR112017007860A2 (pt) método para tratar uma doença de gordura no fígado
BR112016002383A2 (pt) composto, composição herbicida, método para controlar plantas indesejáveis, e, uso de um composto
BR112016002384A2 (pt) composto, composição de herbicida, método para controlar plantas indesejáveis, e, uso de um composto
BR112015016194A2 (pt) compostos, composição, utilização de um composto, método para o combate dos fungos nocivos e semente revestida
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica

Legal Events

Date Code Title Description
FD Lapse